NASDAQ$COGT

Cogent Biosciences Inc · Q1 2026 earnings

Q1 2026 earnings · · Before market open · Investor relations

Briefing

Cogent Biosciences Inc Q1 fiscal 2026: $97.4M net loss, $0.53 loss per share

for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K on file with the SEC.

  • Net loss: $97.4M
  • Diluted EPS: $-0.53
  • Operating income: -103.6M

Headline financials

EPS (adj)

-$0.53

Previous: $0.00
Net Income

-$97.4M

Previous: -$72M-35.2%
Operating Income

-$104M

Previous: -$74.9M-38.3%

Revenue & EPS history

Cogent Biosciences · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+0.9%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+5.0%

Avg return

30 days after

65%

20 / 31 earnings

Positive

+17.8%

Q3 2018

Best reaction

-24.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%-5.4%
Q3 2025-4.4%-9.1%+140.2%
Q2 2025-5.8%-9.0%+7.4%
Q1 2025+2.7%+4.4%+48.4%
Q4 2024-6.3%+0.9%-11.4%
Q3 2024+0.0%-14.4%-19.8%
Q1 2024+0.4%-0.1%+11.1%
Q4 2023+0.7%-2.8%-12.4%
Q3 2023+3.9%+3.8%-2.7%
Q2 2023+7.3%+8.8%+9.4%
Q1 2023-1.5%-2.6%-2.9%
Q4 2022+0.7%-5.1%-13.7%
Q3 2022-5.7%-8.5%-2.6%
Q2 2022+9.6%+12.1%+32.7%
Q1 2022-24.0%-26.8%-10.6%
Q4 2021+4.5%+28.4%+64.6%
Q3 2021+13.7%+12.1%-9.9%
Q2 2021+5.4%+13.4%+3.3%
Q1 2021+1.7%+4.9%+4.0%
Q4 2020+5.9%+5.5%+9.0%
Q3 2020+13.2%+9.8%+14.9%
Q2 2020-11.4%-11.0%-8.3%
Q1 2020+0.5%+17.9%+37.1%
Q4 2019-3.1%-15.5%-18.6%
Q3 2019-10.2%-32.6%-52.1%
Q2 2019+4.4%+9.3%+9.0%
Q1 2019+0.2%-1.1%-26.2%
Q4 2018+8.1%+5.4%-12.3%
Q3 2018+17.8%+18.5%-25.0%
Q2 2018-5.9%-12.8%-27.3%
Q1 2018+4.0%+12.4%+13.6%
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q3 2016
Q3 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro